NCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
Clinical Trials
10 trialsNCT05053308 2023-08-07
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Seoul National University
Phase NA Withdrawn
NCT05037539 2022-08-31
Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain
Department of Medical Services Ministry of Public Health of Thailand
Phase 1/2 Completed
NCT03809455 2020-04-22
FARADI
UNICANCER
Phase 2 Withdrawn
NCT02869321 2019-05-13
ANTALGIP
Central Hospital, Nancy, France
Phase 4 Completed
NCT00125294 2017-09-25
Sublingual Methadone for the Management of Cancer Breakthrough Pain
AHS Cancer Control Alberta
Phase 1 Completed
NCT01326689 2017-03-08
2246-004
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00236041 2014-05-09
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01842893 2013-05-03
ETHYFYL
Ethypharm
Phase 3 Completed
NCT00576173 2010-04-28
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Johnson & Johnson Taiwan Ltd
Phase 4 Completed